

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,
Petitioner

v.

NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owners

Case IPR2021-00816
U.S. Patent No. 9,220,631

**PATENT OWNER'S NOTICE OF WITHDRAWAL OF
ITS CONTINGENT MOTION TO AMEND**

On January 18, 2022, Patent Owner filed a Contingent Motion to Amend in this proceeding. Paper 37. On April 15, 2022, Petitioner filed an Opposition to that Motion. Paper 74. On May 12, 2022, the Board issued its Preliminary Guidance regarding Patent Owner's Motion to Amend. Paper 87. Pursuant to the Board's Pilot Program Concerning Motion to Amend Practice and Procedures, 84 Fed. Reg. 9,497, 9,502 (Mar. 15, 2019), Patent Owner hereby withdraws its Contingent Motion to Amend. Patent Owner reserves all rights, remedies and defenses with respect to the issued claims of U.S. Patent No. 9,220,631.

Dated: May 26, 2022

Respectfully submitted,

By: /Elizabeth J. Holland/
Elizabeth J. Holland (Reg. No. 47,657)
(for filing credentials only)
Allen & Overy LLP
1221 Avenue of the Americas
New York, NY 10020
Phone: (212) 61--6365
Elizabeth.holland@allenoverly.com

Dated: May 26, 2022

Respectfully submitted,

By: /Nicholas K. Mitrokostas/
Nicholas K. Mitrokostas (*pro hac vice*
granted)
Back-up Counsel for Patent Owners
Allen & Overy LLP
One Beacon Street
Boston, Massachusetts 02108
Phone: (857) 353-4500
Fax: (857) 353-4599
Nicholas.Mitrokostas@allenoverly.com

CERTIFICATE OF SERVICE

A copy of this **Patent Owners' Notice of Withdrawal of Its Contingent Motion to Amend** has been served on Petitioner's attorneys of record as follows via electronic mail:

Elizabeth Stotland Weiswasser (Reg. No. 55,721)
Anish R. Desai (Reg. No. 73,760)
Natalie Kennedy (Reg. No. 68,511)
Andrew Gesior (Reg. No. 76,588)
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, NY 10153
T: 212-310-8022
elizabeth.weiswasser@weil.com
anish.desai@weil.com
natalie.kennedy@weil.com
andrew.gesior@weil.com

Brian E. Ferguson (Reg. No. 36,801)
Christopher M. Pepe (Reg. No. 73,851)
Weil, Gotshal & Manges LLP
2001 M Street, N.W., Suite 600
Washington, D.C. 20036
T: 202-682-7000
brian.ferguson@weil.com
christopher.pepe@weil.com
Regeneron.IPR.Service@weil.com

Attorneys for Regeneron Pharmaceuticals, Inc.

Dated: May 26, 2022

By: /Frank ReDavid/
Frank ReDavid
Litigation Specialist
Allen & Overy LLP